Multi-center, open-label, prospective, randomized, parallel group study investigating a CNI-free regimen with Myfortic and Certican in comparison to standard therapy with Myfortic and a calcineurin inhibitor (Sandimmun Optoral or Prograf) in stable renal transplant patients

Trial Profile

Multi-center, open-label, prospective, randomized, parallel group study investigating a CNI-free regimen with Myfortic and Certican in comparison to standard therapy with Myfortic and a calcineurin inhibitor (Sandimmun Optoral or Prograf) in stable renal transplant patients

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2015

At a glance

  • Drugs Everolimus (Primary) ; Ciclosporin; Mycophenolate sodium; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Adverse reactions
  • Acronyms APOLLO
  • Sponsors Novartis
  • Most Recent Events

    • 27 Aug 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
    • 27 Aug 2014 Protocol has been amended to change in the treatment arm with an additional drug addition to the regimen- coticosteroids.
    • 08 Sep 2013 Four-year results presented at the 16th Congress of the European Society for Organ Transplantation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top